$25.07
1.13% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US03209R1032
Symbol
AMPH

Amphastar Pharmaceuticals Inc Stock price

$25.07
+1.57 6.68% 1M
-19.02 43.14% 6M
-12.06 32.48% YTD
-18.00 41.79% 1Y
-8.63 25.61% 3Y
+6.72 36.58% 5Y
+10.28 69.51% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.28 1.13%
ISIN
US03209R1032
Symbol
AMPH

Key metrics

Market capitalization $1.18b
Enterprise Value $1.59b
P/E (TTM) P/E ratio 9.10
EV/FCF (TTM) EV/FCF 10.62
EV/Sales (TTM) EV/Sales 2.18
P/S ratio (TTM) P/S ratio 1.62
P/B ratio (TTM) P/B ratio 1.59
Revenue growth (TTM) Revenue growth 8.05%
Revenue (TTM) Revenue $730.66m
EBIT (operating result TTM) EBIT $194.70m
Free Cash Flow (TTM) Free Cash Flow $150.23m
Cash position $239.32m
EPS (TTM) EPS $2.76
P/E forward 9.10
P/S forward 1.64
EV/Sales forward 2.21
Short interest 13.28%
Show more

Is Amphastar Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Amphastar Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Amphastar Pharmaceuticals Inc forecast:

2x Buy
33%
4x Hold
67%

Analyst Opinions

6 Analysts have issued a Amphastar Pharmaceuticals Inc forecast:

Buy
33%
Hold
67%

Financial data from Amphastar Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
731 731
8% 8%
100%
- Direct Costs 375 375
18% 18%
51%
356 356
1% 1%
49%
- Selling and Administrative Expenses 39 39
7% 7%
5%
- Research and Development Expense 64 64
6% 6%
9%
253 253
4% 4%
35%
- Depreciation and Amortization 58 58
21% 21%
8%
EBIT (Operating Income) EBIT 195 195
9% 9%
27%
Net Profit 142 142
8% 8%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Amphastar Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amphastar Pharmaceuticals Inc Stock News

Neutral
Investors Business Daily
one day ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Positive
Seeking Alpha
10 days ago
Amphastar Pharmaceuticals posted Q1 results last week that beat the bottom-line consensus. The stock appears cheap at under eight times forward earnings, but the company is going through an 'inflection year' with flat revenue growth and declining profits. Growth should return in 2026 thanks to upcoming product launches.  Is the stock cheap enough to buy the recent dip in the shares?
Neutral
Accesswire
12 days ago
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 9, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 2025 Bank of America Health Care Conference on Wednesday, May 14th, 2025, at 1:40 pm PT. For access, visit Amphastar's Pharmaceuticals website at...
More Amphastar Pharmaceuticals Inc News

Company Profile

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Head office United States
CEO Yong Zhang
Employees 2,028
Founded 1996
Website www.amphastar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today